HomeInvesting NewsNovavax Experiences a 52-Week Low as Pfizer and Moderna Receive FDA Approval...

Novavax Experiences a 52-Week Low as Pfizer and Moderna Receive FDA Approval for Improved Boosters

Published on

Novavax (NASDAQ:NVAX)

After the FDA announced U.S. regulatory approval for Omicron-adjusted booster vaccinations created by competing COVID-19 vaccine manufacturers Pfizer (NYSE:PFE)/BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA), the shares of Novavax (NASDAQ:NVAX) dropped to a new 52-week low on Wednesday.

The last company to enroll in the COVID-19 vaccination campaign in the United States was a Maryland-based biotech, whose regulators approved its protein-based vaccine for those 18 years of age and older in July.

However, when the pandemic’s impact diminished, the business’s vaccine sales suffered. In August, the company announced a significant Q2 sales miss and cut its 2022 revenue projection.

The monovalent booster injections created by Pfizer (NYSE:PFE)/BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) will no longer be recommended as booster shots for those 12 years of age and older, the FDA announced today in announcing its decision.

The recently approved bivalent vaccinations are intended to protect against both the primary viral strain and the Omicron BA.4 and BA.5 subvariants. The monovalent boosters that had previously been cleared, however, only affected the original COVID-19 strain.

Recently, Novavax (NASDAQ:NVAX) reported that it had submitted applications to the FDA for approval to use the NVX-CoV2373 COVID-19 vaccine as a booster dose. The business anticipates submitting regulatory submissions in Q4 2022 in order to get FDA approval for an Omicron-containing vaccine.

Vaccine Approval

Although the COVID-19 vaccine Nuvaxovid continues to score regulatory successes, the stock’s Monday performance would have you believe otherwise. Despite a very positive regulatory outcome for the firm and its jab, it declined by 2%, roughly mirroring the day’s decline of the S&P 500 index.

Recently, Nuvaxovid’s use in people between the ages of 12 and 17 was approved by the Food and Drug Administration (FDA), according to Novavax. The vaccine’s emergency use authorization (EUA), which was first granted by the American regulator in mid-July, is now extended to include that population.

Featured Image-  Megapixl @Filmfoto

See Disclaimer Please

Latest News

Recent Surge in Tesla Stock: Exactly What Caused It?

Tesla Stock (NASDAQ:TSLA) As of 11:30 a.m ET on Friday, Tesla stock was up 2.3%...

Here’s Why Carvana Stock Fell Quite So Much as 23.7% This Week

Carvana Stock (NYSE:CVNA) According to data provided by S&P Global Market Intelligence, Carvana stock fell...

Here’s Why Tellurian Stock Is Rising Again Today

Tellurian Stock (NYSEMKT:TELL) Tellurian stock was up 6.5% as of 11:06 p.m. ET today after...

Is It Time to Buy Chewy Stock?

Chewy Stock (NYSE:CHWY) Pet supplies are one of the few consumer goods that do well,...

More like this

2 Casino Stocks You Should Consider

With a recession on the horizon, investors must be more selective than ever. Analysts...

(Exxon Mobil Stock) Exxon Ceo Warns Biden Administration Against Restricting Fuel Exports

Exxon (Exxon Mobil Stock) opposes calls for oil corporations to reduce international exports and...

Apple Stock Loses $120 Billion Because of a Rare Downgrade

Apple stock just took a significant knock after it was once considered to be...

Meta Stock Tops Morningstar List of the Most Undervalued Stocks 

Morningstar compiled a list of the most undervalued stocks among those with a large...

Hd Stock up as Foundation to Contribute Up to $1 Million to Aid Communities Affected by Hurricane Ian

HD stock was trading at $280.23 as of 12:55 PM EDT. The Home Depot Foundation...

Making the Cut: Micron (Micron Stock)

Micron Technology Inc (Micron Stock) latest outlook brings expectations back to normal, although the...